( May 23, 2025, 2:18 PM EDT) -- WASHINGTON, D.C. — A panel in the Federal Circuit U.S. Court of Appeals held May 22 that the Patent Trial and Appeal Board (PTAB) did not err when it ruled that a biopharmaceutical company’s patents on a hemophilia gene therapy treatment were unpatentable as obvious, affirming the board’s finding in an inter partes review (IPR) proceeding brought by Pfizer Inc....